MetaStat

MetaStat Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of MetaStat (MTST) as of Oct 6, 2026 is 82.89 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 37.23 % — a change of 122.68% (higher).

Cash Conversion

82.89 %

YoY

122.68%

Last updated:

Cash Conversion Rate (OCF/Net Income) of MetaStat is 2026 82.89 % . Cash Conversion Rate (OCF/Net Income) of MetaStat was 2025 37.23 % . It decreases by 122.68% higher compared to the previous year.

The MetaStat Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2014
41.00 USD
Jan 1, 2015
43.52 USD
Jan 1, 2016
52.44 USD
Jan 1, 2017
37.23 USD
Jan 1, 2018
82.89 USD
The MetaStat Cash Conversion history
YEARCash ConversionYoY
82.89 %+122.68%
37.23 %-29.01%
52.44 %+20.50%
43.52 %+6.15%
41.00 %—
Access this data via the Eulerpool API

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

Cash Conversion Rate (OCF/Net Income) of MetaStat is 82.89 % in 2026.

Cash Conversion Rate (OCF/Net Income) of MetaStat changed from 37.23 % to 82.89 %, representing a 122.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) MetaStat since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s MetaStat with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — MetaStat

All Key Metrics — MetaStat